Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.43 - $1.24 $12,729 - $36,708
-29,604 Closed
0 $0
Q1 2022

May 13, 2022

SELL
$0.74 - $1.79 $1,541 - $3,728
-2,083 Reduced 6.57%
29,604 $36,000
Q4 2021

Feb 11, 2022

SELL
$1.69 - $2.46 $1,602 - $2,332
-948 Reduced 2.9%
31,687 $55,000
Q3 2021

Nov 12, 2021

SELL
$2.38 - $3.77 $1,846 - $2,925
-776 Reduced 2.32%
32,635 $78,000
Q2 2021

Aug 13, 2021

BUY
$3.49 - $5.51 $59,413 - $93,802
17,024 Added 103.89%
33,411 $122,000
Q1 2021

May 07, 2021

BUY
$5.37 - $10.72 $236 - $471
44 Added 0.27%
16,387 $91,000
Q4 2020

Feb 12, 2021

BUY
$3.08 - $7.79 $4,814 - $12,175
1,563 Added 10.58%
16,343 $124,000
Q3 2020

Nov 04, 2020

SELL
$2.02 - $3.08 $678 - $1,034
-336 Reduced 2.22%
14,780 $30,000
Q2 2020

Aug 12, 2020

BUY
$2.1 - $3.42 $7,312 - $11,908
3,482 Added 29.93%
15,116 $44,000
Q1 2020

May 04, 2020

SELL
$2.31 - $4.43 $1,554 - $2,981
-673 Reduced 5.47%
11,634 $28,000
Q4 2019

Feb 05, 2020

SELL
$2.82 - $12.9 $290 - $1,328
-103 Reduced 0.83%
12,307 $55,000
Q3 2019

Nov 08, 2019

BUY
$4.33 - $11.64 $12,076 - $32,463
2,789 Added 28.99%
12,410 $128,000
Q2 2019

Aug 13, 2019

BUY
$4.6 - $10.13 $8,505 - $18,730
1,849 Added 23.79%
9,621 $55,000
Q1 2019

May 06, 2019

SELL
$7.19 - $32.37 $1,811 - $8,157
-252 Reduced 3.14%
7,772 $72,000
Q4 2018

Feb 13, 2019

SELL
$21.32 - $46.34 $1,300 - $2,826
-61 Reduced 0.75%
8,024 $215,000
Q3 2018

Nov 09, 2018

BUY
$36.35 - $51.7 $78,297 - $111,361
2,154 Added 36.32%
8,085 $381,000
Q2 2018

Aug 08, 2018

BUY
$7.33 - $43.15 $938 - $5,523
128 Added 2.21%
5,931 $211,000
Q1 2018

May 07, 2018

BUY
$7.19 - $33.17 $41,723 - $192,485
5,803 New
5,803 $44,000

Others Institutions Holding SLDB

About Solid Biosciences Inc.


  • Ticker SLDB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 7,533,080
  • Market Cap $36.5M
  • Description
  • Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...
More about SLDB
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.